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Abstract
Background In health economic literature, checklists or best practice recommendations on model validation/credibility always 
declare verification of the programmed model as a fundamental step, such as ‘is the model implemented correctly and does 
the implementation accurately represent the conceptual model?’ However, to date, little operational guidance for the model 
verification process has been given. In this study, we aimed to create an operational checklist for model users or reviewers to 
verify the technical implementation of health economic decision analytical models and document their verification efforts.
Methods Literature on model validation, verification, programming errors and credibility was reviewed systematically 
from scientific databases. An initial beta version of the checklist was developed based on the checklists/tests identified from 
the literature and from authors’ previous modeling/appraisal experience. Next, the first draft checklist was presented to a 
number of health economists on several occasions and was tested on different models (built in different software, developed 
by different stakeholders, including drug manufacturers, consultancies or academia), each time leading to an update of the 
checklist and culminating in the final version of the TECHnical VERification (TECH-VER) checklist, introduced in this paper.
Results The TECH-VER necessitates a model reviewer (preferably independent), an executable and transparent model, its input 
sources, and detailed documentation (e.g. technical report/scientific paper) in which the conceptual model, its implementation, 
programmed model inputs, and results are reported. The TECH-VER checklist consists of five domains: (1) input calculations; (2) 
event-state (patient flow) calculations; (3) result calculations; (4) uncertainty analysis calculations; and (5) other overall checks 
(e.g. validity or interface). The first four domains reflect the verification of the components of a typical health economic model. 
For these domains, as a prerequisite of verification tests, the reviewer should identify the relevant calculations in the electronic 
model and assess the provided justifications for the methods used in the identified calculations. For this purpose, we recom-
mend completeness/consistency checks. Afterwards, the verification tests can be conducted for the calculations in each of these 
stages by checking the correctness of the implementation of these calculations. For this purpose, the following type of tests are 
recommended in consecutive order: (i) black-box tests, i.e. checking if model calculations are in line with a priori expectations; 
(ii) white-box testing, i.e. going through the program code details line by line, or cell by cell (recommended for some crucial 
calculations and if there are some unexpected results from the black-box tests); and (iii) model replication/parallel programming 
(recommended only in certain situations, and if the issues related to the identified unexpected results from black-box tests could 
not be resolved through white-box testing). To reduce the time burden of model verification, we suggest a hierarchical order in 
tests i–iii, where going to the next step is necessary when the previous step fails.
Conclusions The TECH-VER checklist is a comprehensive checklist for the technical verification of decision analytical 
models, aiming to help identify model implementation errors and their root causes while improving the transparency and 
efficiency of the verification efforts. In addition to external reviews, we consider that the TECH-VER can be used as an inter-
nal training and quality control tool for new health economists, while developing their initial models. It is the authors’ aim 
that the TECH-VER checklist transforms itself to an open-source living document, with possible future versions, or ‘bolt-on’ 
extensions for specific applications with additional ‘fit-for-purpose’ tests, as well as ‘tips and tricks’ and some demonstra-
tive error examples. For this reason, the TECH-VER checklist and the list of black-box tests created in this paper and a few 
model verification examples is uploaded to an open access, online platform (github and the website of the institute), where 
other users will also be able to upload their original verification efforts and tests.
https ://publo ns.com/resea rcher /31065 88/maure en-rutte n-van-molke n/.
Extended author information available on the last page of the article
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Key Points for Decision Makers 
Model verification is an integral part of the model 
validation process and aims to ensure that the model 
calculates what it intends to calculate. The TECHnical 
VERification (TECH-VER) checklist aims to provide 
a documenting framework to improve efficiency in the 
model verification efforts and to help identify modeling 
errors and their root causes in a systematic way.
The TECH-VER checklist presents an objective, trans-
parent way to assist the end user of the model in forming 
a judgment on the model’s verification status, with the 
end-goal to improve trust from various stakeholders (e.g. 
patients, payers) in the model outcomes in health tech-
nology assessment decision-making processes.
1 Introduction
Economic evaluations are undertaken in several jurisdictions 
around the world to inform decision making regarding the 
reimbursement of particular medications and/or other inter-
ventions. These economic evaluations are often based on 
decision analytic models that synthesize evidence from dif-
ferent sources, link intermediate outcomes to final outcomes, 
extrapolate short-term evidence to longer-term outcomes, 
and make the effects/trade-offs surrounding the treatment 
choices, as well as the key assumptions, explicit.
As the common aphorism generally attributed to George 
Box suggests, all models are wrong, but some are useful. All 
models are wrong since, by definition, all involve simplifi-
cation and mathematical abstraction of the complex real-
ity, which leads to deviation from the reality. On the other 
hand, these simplifications enable us to understand complex 
phenomena in the reality that have not been or cannot be 
observed empirically. Henceforth, some models are useful 
and we need them in health economics just like in other 
scientific fields.
In order to use health economic models for decision 
making, their results should be trustable. Therefore, in 
the work by Caro et al. [1] and Tappenden and Chillcott 
[2], the importance of model credibility was emphasized. 
In both studies, the model credibility was defined as the 
notion, which determines the extent to which the results of 
a model can be trusted and the level of confidence that can 
be placed in the model during the decision-making process. 
Tappenden and Chillcott [2] developed a taxonomy, which 
segregates threats to model credibility into three broad cate-
gories: (1) unequivocal errors; (2) violations; and (3) matters 
of judgment. In the same paper, the taxonomized credibility 
threats were mapped across the main elements of the model 
development process (which can be seen in Fig. 1), and a 
range of suggested processes and techniques were listed for 
avoiding and identifying these credibility threats.
Well-documented model validation and verification pro-
cesses do not guarantee the correctness of the results of a 
model, but might improve the model credibility among its 
users and decision makers. There is no consensus on the 
definitions of model validation and verification in the litera-
ture, however the most commonly accepted definition from 
the software/operations research literature (e.g. Sargent [3]) 
describe validation as the act of evaluating whether a model 
is a proper and sufficient representation of the system it is 
intended to represent, in view of a specific application. On 
the other hand, verification focuses on whether a model is 
implemented correctly and assures that the model implemen-
tation (i.e. programming in the relevant software platform) 
accurately represents the conceptual model description [3]. 
Following from these definitions, it can be interpreted that 
the verification of a model should be considered as a pre-
requisite, as well as a constituent, of the validation process. 
Model validity is conditional on the status of its verification 
because a wrongly implemented model would automatically 
fail to represent the real world/system accurately, even though 
the conceptualization of the real world/system was right.
Despite the acknowledgment of the importance of verifi-
cation in the health technology assessment (HTA) literature, 
there are currently no established guidelines on how to test 
and verify decision-analytic models for health economic 
evaluations. However, in a broader context, a large body of 
literature exists on software verification, mainly focusing on 
box-based testing approaches (e.g. Limaye [23]). Generally, 
software verification tests can be categorized into white-box 
testing (those performed by the software developer with the 
knowledge of the interworkings of the functions comprising 
the code base, such as scrutinizing the code line by line) 
and black-box testing (those performed without having to 
have knowledge of the interworkings of the code, such as 
running the code with a specific setting and given inputs 
and assessing if the output of the code is in line with the 
expectations or not).
The current study aims to create an operational checklist 
and documenting structure to support the technical verifica-
tion process of health economic decision analytical models. 
For this purpose, a number of black-box and white-box tests 
for health economic models were collated and the TECH-
nical VERification (TECH-VER) checklist was developed, 
which encapsulates the necessary verification efforts for the 
major components of a health economic model.
The TECH-VER checklist aims to improve transparency 
and efficiency by streamlining the verification process and 
its documentation, and to help identify modeling errors and 
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their root causes in a more systematic manner. Furthermore, 
new health economic modelers can use TECH-VER as a 
self-learning tool since they can integrate some of the veri-
fication tests while they are building the model.
In order to apply the TECH-VER checklist completely, 
one needs a model reviewer (preferably different from the 
model developer to prevent possible bias), a fully accessible 
and conceptually valid electronic model (e.g. without any 
hidden/locked parts) accompanied with a transparent tech-
nical report/evidence dossier, which details the conceptual 
model design, inputs used with their references, descrip-
tion of all the calculations in the model, and the results. It 
should be noted that the steps in TECH-VER can also be 
applied partially to a work-in-progress model, throughout 
the development process. The authors consider that it would 
be most efficient if TECH-VER is used in conjunction with 
other validation efforts (e.g. conceptual or face validity) as 
these efforts are highly interdependent and the verification 
of a conceptually wrong model (e.g. a model that estimates 
total life expectancy of a cohort by rolling a die) would be 
a waste of time.
In the next section, the methods used while building the 
TECH-VER checklist are described.
2  Methods
Development of the checklist consisted of the following 
steps:
• literature review to identify studies on model credibility, 
validation, and verification;
• development of the initial list of verification steps from 
both the literature and authors’ experiences;
• iterative revision after each application of the TECH-
VER checklist to a different model;
• revision after feedback from discussions with other 
health economists.
2.1  Literature Review
A literature search was conducted on the EMBASE and 
MEDLINE databases using the interface in Embase.com. 
The search filters were targeting for identifying some spe-
cific keyword variations of ‘checklist’, ‘guideline’, ‘valida-
tion’, ‘verification’, ‘error’, ‘questionnaire’ and ‘credibil-
ity’, in the titles and abstracts of the published economic 
modeling studies for cost-effectiveness analysis/HTA. The 
search strategy is presented in Appendix Table 3. The data-
base output, including all indexed fields per record (e.g. title, 
authors, abstract), was exported to Endnote version X7.4, 
where the hits were de-duplicated.
From the articles retrieved from the MEDLINE and 
EMBASE libraries, the relevant references were selected 
using a two-step selection procedure, based on the following.
1. Screening of the title and abstract: This step yielded the 
articles that were assessed in full-text. The major top-
ics of the articles were assessed on relevancy for the 
Fig. 1  Model development process taken from Tappenden and Chillcott [2]
1394 N. C. Büyükkaramikli et al.
objectives by title and abstract. In this step, articles that 
seemed to contain relevant data for the objectives were 
selected for full-text screening, while articles that did 
not seem to contain relevant data were not selected for 
full-text assessment.
2. Screening of the full article: The articles selected during 
the first phase were assessed in full text. PDF files of the 
original articles were downloaded and stored. Articles 
were included if the reported information was relevant, 
based on the inclusion and exclusion criteria, and of suf-
ficient quality and sample size.
The process of selection and inclusion and exclusion of 
articles was registered in an Endnote library by one of the 
researchers (NCB), and the inclusion of the articles was 
supervised by another researcher (MA). The exclusion cri-
teria applied in the selection procedure are reported in the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) flowchart. The list of inclusion criteria 
applied during the selection process is explained below.
• Period of publication: From inception of the databases 
until May 2019.
• Country/language: No restriction.
• Study design/type: Checklists, questionnaires, tests 
or systematic reporting of the efforts on model errors/
model verification technical validation for HTA or cost-
effectiveness analysis.
2.2  Initial (Beta Version) Checklist
An initial checklist was formed, based on the findings from 
the existing studies identified from the literature review, as 
well as the authors’ own experience with model checking 
and reviewing. The black-box tests extracted from the litera-
ture (i.e. Tappenden and Chilcott [2], Dasbach and Elbasha 
[6], Hoogendoorn et al. [24]) were elaborated by additional 
de novo black-/white-box and replication-based tests created 
by the authors, and all these tests were reordered according 
to the framework created by the authors, which compartmen-
talizes the model-based calculations to different modules.
2.3  Iterative Revision of the Beta Checklist After 
Each Application
After the initial checklist had been developed, it was applied 
in several health economic models by several model review-
ers. The models varied in terms of their developers (pharma-
ceutical companies, academic institute, or consultant firms), 
their purpose (to support reimbursement submissions, give 
early strategic advice in market access, for academic pub-
lication) and underlying clinical evidence maturity (e.g. 
the clinical effectiveness claim was based on systematic 
synthesis of randomized controlled trials (RCTs), a single 
RCT, evidence based on a non-randomized study, or even 
just clinical expectations used in sampling power calcula-
tions). TECH-VER was also applied in some of the students’ 
models. These models were developed for the graduation-
level course on health economic modeling or for the Master’s 
Degree theses, both at Erasmus School of Health Policy and 
Management (ESHPM) in Erasmus University Rotterdam.
After all applicable black-box-type tests of the most 
recent version of the checklist were performed, each model 
was checked cell by cell (if the model implementation was 
conducted in a spreadsheet environment), or line by line (if 
the implementation was conducted using a programming 
code such as R or Visual Basic Applications for Excel®), as 
part of the white-box testing procedure. If additional errors 
or problems in the model implementation were identified 
during these white-box testing efforts, new black-box test-
type questions were added or the existing black-box test-type 
questions were revised, in order to increase the sensitivity 
of the black-box type tests of the checklist. This iterative 
process was performed each time the checklist was filled in 
for a new model.
2.4  Revision Based on Feedback from Other Health 
Economists
The checklist was discussed with other health economists 
in various instances.
1. A workshop organized with health economists at Eras-
mus University Rotterdam.
2. An elaborate discussion of the checklist with several 
health economists from other Dutch/Belgian academic 
centers in the Low Lands Health Economic Study Group 
(lolaHESG) in May 2016.
3. A workshop organized with health economists from 
industry and international academic centers at the Inter-
national Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) Annual Congress in November 2016.
4. Revision based on comments from the referee(s) and the 
editor(s) after submitting the manuscript for publication 
in PharmacoEconomics.
2.4.1  Workshop Organized with Health Economists 
at Erasmus University Rotterdam
The checklist was distributed to an audience of health econo-
mists 1 week before a workshop (2.5 h) on model verifica-
tion, where the checklist was presented and discussed. This 
workshop was conducted at the Erasmus School of Health 
Policy and Management and the Institute for Medical Tech-
nology Assessment of the Erasmus University Rotterdam, 
with a group of health economists (n  = 12) with varying 
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levels of experience in health economic modeling (minimum 
experience of 2 years; all participants had developed their 
own economic models; a majority worked only with decision 
trees/state transition models in a spreadsheet environment; 
most had published their own models or were in the process 
of publishing; and some were very experienced modelers 
involved in the appraisal processes of medical technologies 
for different national HTA bodies such as National Institutes 
for Health and Care Excellence [NICE] from the UK or the 
Healthcare Institute [ZiN] from The Netherlands). Their 
feedback on the checklist and its usability was collected in 
a separate form. Elicited feedback and suggestions from the 
audience played a key role in the revision of the checklist.
2.4.2  Discussion of the TECHnical VERification (TECH‑VER) 
at the Low Lands Health Economics Study Group 
Annual Meeting (May 2016)
The Low Lands Health Economics Study Group (lolaHESG) 
is inspired by the Health Economists’ Study Group (HESG) 
in the UK, and supports and promotes the work of health 
economists working at Dutch and Belgian research institutes. 
During the annual meetings, participants meet in groups to 
discuss papers that had been precirculated. These 1-h dis-
cussions were led by a discussant who presented the paper.
The TECH-VER checklist was presented and discussed 
during the lolaHESG meeting in May 2016, among a group 
of health economics researchers (n ≈ 25) from various 
Dutch/Belgian academic centers. The feedback from the dis-
cussant and the audience were incorporated into the revision 
of the checklist.
2.4.3  Model Verification Workshop at the International 
Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) Annual European Congress 
(November 2016)
A workshop on model verification was organized together 
with a health economist from a consultancy that provides 
services to the pharmaceutical industry and a health econo-
mist from an academic institution in UK, which also par-
ticipates in NICE Technology Appraisals as an independent 
academic Evidence Review Group (ERG). TECH-VER was 
presented to an audience of health economists (n ~ 120) from 
international academic centers, as well as professionals from 
the industry and from the government. The feedback from 
this audience, which was elicited by interactive questions 
and follow-up communication, were incorporated into the 
revision of the checklist. After the workshop, the full version 
of the checklist was shared via hard copy/email with those 
attendants who had indicated their interest, whose feedback 
was collected in person/via email.
2.4.4  Revision Based on the Comments from the Referee(s) 
and the Editor(s)
After submitting the previous version of this manuscript for 
publication in PharmacoEconomics, we received a list of 
suggestions to improve the functionality of the TECH-VER. 
At each revision round, the authors attempted to incorpo-
rate the feedback suggestions from the referee(s) and the 
editor(s), which led to the most recent updates in the TECH-
VER. These suggestions were mostly related to the rear-
rangement and prioritization of the verification efforts in 
the TECH-VER to improve its potential usability in time-
constrained projects.
3  Results
3.1  Literature Review Results
Based on the search, a total of 3451 unique records were 
identified from the MEDLINE and EMBASE databases 
(Fig. 2). Of those, 3383 records were excluded based on 
their title and/or abstract. Sixty-eight articles were screened 
in full-text and 15 articles were included after applying the 
inclusion and exclusion criteria [2, 4–16, 24]. The resulting 
PRISMA diagram can be seen in Fig. 2. The main reasons 
for exclusion were: 
• studies were checklist/guidance/recommendations on 
topics other than model validation/verification, for 
instance the checklists on the reporting of economic 
evaluations, or checklists to evaluate the overall quality 
of economic evaluations (n  = 21);
• studies reported some model validation efforts but no 
model verification effort (n  = 21);
• studies on other topics on model validity theory, for 
instance statistical tests for external validation (n  = 10);
• full-text was not accessible or the study was not related 
to HTA (n  = 2).
Among the 15 included articles, the majority of the stud-
ies (n  = 10) were model-based cost-effectiveness analysis 
studies, which reported some limited amount of verification 
efforts [7–16]. The reporting of the verification efforts in 
none of these studies was systematic. The majority of the 
studies just reported a very brief summary description of 
the verification efforts, such as “the model has been thor-
oughly tested and de-bugged, including artificial simulations 
designed to reveal errors in both logic and programming” 
(Willis et al. [14]) or “The technical functioning was tested 
by means of an extensive sensitivity analysis. Extreme 
values of the input variables were used, and the model’s 
actual outputs were compared with expected outcomes.” 
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(Hammerschmidt et al. [8]). A few studies reported only 
one type of verification effort, for instance the study by Cox 
et al. [7] attempted to replicate the base case of another pub-
lished model in the literature, and compared the literature- 
and replication-based results with each other. Hence, these 
10 studies were not used while forming the initial version 
of TECH-VER.
Two of the included articles were guidelines/best prac-
tice recommendations on the model validation process [4, 
5]. In these studies, model verification was explicitly men-
tioned as one of the components of the model validation 
process, however no operational procedure/black-box test 
list was provided for model verification. Therefore, these 
two studies were not used while forming the initial version 
of TECH-VER.
Additionally, we included three other studies in our litera-
ture review [2, 6, 24]. These papers explicitly reported vari-
ous types of black-box testing [2, 6, 24]. The first study, by 
Tappenden and Chilcott [2], provided a taxonomy of model 
errors and credibility threats, and linked them to model 
development processes. Together with this error taxonomy, 
Tappenden and Chilcott also provided a list of black-box 
tests and recommendations to help avoid and identify model 
errors/credibility threats.
The second study, by Hoogendoorn et al. [25], presented 
a dynamic population-level model for assessing the cost 
effectiveness of smoking cessation programs in patients with 
chronic obstructive pulmonary disease. Although the paper 
itself was excluded for not reporting any validation/verifi-
cation efforts, another scientific report by the same authors 
[24] was cited. This cited report documented their validation 
and verification efforts, including a list of black-box tests, 
and was therefore included [24].
The third study, by Dasbach and Elbasha [6], pinpointed 
the necessity and the lack of a verification guidance, and 
gave a brief overview of verification methods used in soft-
ware engineering and other fields. These researchers also 
uploaded a list of black-box tests, for model verification pur-
poses, to an open-access software coding platform (GitHub).
The black-box tests found from these studies identified 
from the literature review were considered in the forma-
tion of the initial beta version of the TECH-VER, which 
was extended by additional black-box tests and restructured 
based on the feedback suggestions from other health econo-
mists, as outlined in Sects. 2.3 and 2.4.
3.2  TECH‑VER Checklist
The TECH-VER checklist (Table 1) consists of the following 
five verification stages. 
1. Model input (pre-analysis) calculations.
Fig. 2  PRISMA flowchart for the literature review on model verification. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-
Analyses, HTA health technology assessment
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2. Event/state calculations.
3. Result calculations.
4. Uncertainty analysis calculations.
5. Overall validation/other supplementary checks.
The first four stages represent the calculations of the 
‘compartmentalized modules’ of a typical decision analyti-
cal model.
In the verification stages of the compartmentalized mod-
ules (stages 1–4), as a prerequisite, the reviewer is first asked 
to identify the relevant calculations in the electronic model 
and to assess the appropriateness of the provided justifica-
tions for the methods/approaches/assumptions used in each 
of the identified calculations. For this prerequisite step, we 
recommend the reviewer checks the completeness and con-
sistency of the relevant calculations.
Completeness/consistency test: This part involves locat-
ing the calculations to be tested in the model and assessing 
their completeness (e.g. no hidden sheets/ranges/modules, 
no links to external programs, no hardcoded values, and no 
password protection) and assessing the consistency of the 
calculations (model implementation versus description in 
the report versus description/values in the reference source).
After this prerequisite step is completed, the correctness 
of the implementation of the model calculations needs to 
be checked. For this correctness check, the following tests 
should be applied in a consecutive and hierarchical order.
• Black-box testing: This involves checking if the related 
model calculations show results in line with a priori 
expectations, not only for plausible parameter inputs but 
also for extreme value parameters or probabilistic inputs.
• White-box testing: This involves checking the detailed 
model calculations that are being inspected, such as by 
going through the related code carefully, line by line, 
or by scrutinizing the formulae in all related ranges in a 
spreadsheet, cell by cell.
• Replication-based tests: These involve replication efforts 
of the calculations being inspected. The reviewer will try 
to replicate/re-perform the calculations using the same or 
different software (or even by pen and paper, if possible).
The tests listed above are sorted in an increasing order in 
terms of the expected time investment required for each test 
type, if they are conducted on the whole model. For model 
reviews that need to be conducted under a time constraint, 
we would like to limit the white-box and replication-based 
testing for specific, essential calculations only and under 
certain circumstances. Therefore, the tests can be conducted 
based on the suggested hierarchical order, visualized in 
Fig. 3.
For each verification stage of the compartmentalized 
modules, after the completeness/consistency checks are 
completed, a wide-ranging list of model-specific black-box 
tests needs to be prepared by the model reviewer. We pre-
sent a list of black-box tests that can be useful, while model 
reviewers are creating their own lists, in Table 2. These types 
of tests aim to detect unexpected model behaviors, which 
might be caused by one (or more) error(s) in the electronic 
model.
After the black-box tests are conducted, white-box tests 
are recommended only for a priori selected essential cal-
culations (such as calculation of the cycle-based technol-
ogy acquisition costs, transition probabilities, or how these 
probabilities informed the transitions in certain cycles, etc.). 
Additionally, the white-box tests are recommended to locate 
the root cause of an unexpected model behavior, signaled by 
the black-box tests. Replication tests are recommended only 
in certain circumstances, such as when white-box tests fail 
to detect the root cause of an unexpected model behavior, 
or when white-box tests seem to be more challenging due to 
the non-transparent, complex programming in the reviewed 
model.
Note that some of the software-specific built-in functions/
tools (e.g. ‘Error checking’ and ‘Evaluate formula’ options 
in Microsoft  Excel®, or debug toolbox in Visual Basic for 
Applications for  Excel®) can be used during the white-box 
testing efforts. However, these tools and others do not negate 
the necessity of detailed cell-by-cell or line-by-line inspec-
tion by the reviewer during the white-box tests. Similarly, 
the  Inquire® tool embedded to Excel can prove to be useful 
in the completeness/consistency checks in spreadsheet envi-
ronments as this tool can identify hidden sheets/ranges and 
hardcoded formulae in spreadsheet models.
In the next subsections, we briefly describe the scope and 
importance of each verification stage, give a couple of typi-
cal error examples that could potentially be detected by that 
verification stage, and provide further guidance on how to 
report the description and results of the verification efforts.
3.2.1  Verification Stage 1: Model Input/Pre‑Analysis 
Calculations
This verification stage focuses on the pre-analysis calcula-
tions that yield direct-to-use, cycle-based, or event-based 
model inputs from the reference source inputs. Often, these 
pre-analysis calculations might be performed outside the 
electronic model, using another statistical software (e.g. 
R, STATA). If these calculations are inaccessible to the 
reviewer, they should be reported as missing during the 
completeness and consistency checks.
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Some real-life examples
• Errors in the pre-analysis calculations for deriving tran-
sition probabilities: In the NICE company submission 
for secukinumab for ankylosing spondylitis [17], an error 
was detected in the network meta-analysis (NMA) that 
was used in generating the treatment-specific response 
probabilities for the electronic model. The error was 
detected after the ERG realized that the company’s NMA 
could not be replicated.
• Errors in the pre-analysis calculations for deriving tran-
sition probabilities: In one of the student group’s models 
for the health economics graduate-level course project, 
errors were detected after a strong dissimilarity between 
the overall survival (OS) extrapolation from the students’ 
model and the corresponding Kaplan–Meier curve from 
the trial was observed. Furthermore, the Weibull OS 
extrapolation from the students’ model did not demon-
strate the characteristics of the distribution (i.e. survival 
function was not non-increasing and the associated 
hazard rate did not demonstrate a monotone behavior 
in time). Later, it was found that this dissimilarity and 
the strange behavior of the extrapolation was caused by 
problems with the X-Y digitization process while gener-
ating pseudo patient-level data, and by the wrong transla-
tion of the log-transformed regression outputs to use in 
the corresponding distribution function for the survival 
extrapolation.
• Errors in the pre-analysis calculations for deriving cost 
inputs: In the NICE appraisal of pomalidomide with 
dexamethasone for relapsed/refractory multiple myeloma 
[18], the ERG identified an error in the weekly resource 
use cost estimation of the company, when the calculated 
resource use estimate of the company differed signifi-
cantly from the estimate obtained from the back of the 
envelope calculations from the ERG. Later, it was dis-
covered that the error was due to the fact that instead 
of dividing the annual resource use estimate by 52, the 
company wrongly converted the annual estimate to the 
weekly probability of using a resource.
• Errors in the pre-analysis calculations for deriving cost 
and utility inputs: In one of the student group’s models 
for the health economics graduate-level course project, 
errors were detected in the treatment acquisition cost cal-
culations. These costs should be dependent on weight; 
the errors were detected when the cycle-based costs for 
drug acquisition remained unchanged for different weight 
assumptions, and the ‘no wastage’ scenario generated the 
same result as the ‘with wastage’ scenario. It was later 
found that a constant drug acquisition cost was always 
assumed. In the same model, another error in calculating 
the adverse event utility decrement was identified. The 
overall utility value corresponding to the cycle during 
which this utility decrement was applied was lower than 
zero. It was later realized that the students did not use 
the same time units while scaling the average duration 
for that adverse event (in days) to the cycle length dura-
tion (1 week), which overestimated the adverse event-
associated utility decrements.
The pre-analysis calculations can be categorized as 
follows:
• transition probabilities (e.g. NMA, other statistical mod-
els, survival analysis techniques, etc.).
• costs (e.g. calculating cycle/event-based estimates).
• utilities/other health outcomes (e.g. calculating cycle/
event-based estimates).
• other calculations.
While checking the correctness of the type of calculations 
above, the model reviewer should follow the outlined steps 
in Table 1 (prerequisite checks, black-box, white-box and 
replication-based tests in hierarchical order). Crucial calcu-
lations for white-box testing in this stage can be calculation 
of the treatment (e.g. drug/device) acquisition cost per cycle, 
or how the transition probabilities are generated and how the 
treatment effectiveness is applied.
3.2.2  Verification Stage 2: Event/State Calculations
This verification stage focuses on the event/state-based cal-
culations in the electronic model. These calculations might 
involve (but are not limited to) the following calculations:
• unfolding of decision and chance nodes in a decision tree.
• calculation of the distribution of cohorts among different 
health states at a given cycle in a state transition model 
(e.g. Markov trace).
• determining when/which type of event will occur next, 
at a given time in a discrete event simulation model.
• assignment of costs/QALYs/other health outcomes to the 
relevant states or events in the electronic model.
The verification checks of these calculations are essential 
as the errors that can be detected in this verification stage 
might have a substantial impact on the decision. Crucial 
calculations for white-box testing in this stage can be the 
way in which transition probabilities are used in calculat-
ing the number of patients in each state (or experiencing an 
event) for a couple of cycles, and how costs and utilities are 
assigned to these states and events.
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Some real-life examples
• Error in the cohort trace: In the electronic model 
attached to the NICE company submission of idelalisib 
for refractory follicular lymphoma [19], the ERG identi-
fied an error in the Markov trace, which led to a negative 
number of transitions between certain states of the model 
at certain times. This error could have been detected by 
the black-box tests suggested for verification stage 2 
(event/state calculations), for instance by checking if all 
the transition probabilities are greater than or equal to 
zero.
• Error in time to event generation: In the electronic model 
used in the same appraisal, for each patient that has recently 
progressed, his/her time to death after progression is esti-
mated from a parametric extrapolation curve fitted to post-
progression survival data from the long-term follow-up 
from another trial. However, at monthly intervals after 
Table 1  TECH-VER checklist
1- Model input (pre-analysis) calculaons: this 
verificaon stage checks the pre-analysis calculaons 
that yield direct model inputs (e.g. transion 
probabilies, cycle-based or event-based costs and 
ulies) from reference source inputs
2- Event/state calculaons: this verificaon stage 
checks the event/state calculaons that determine the 
paent flow/disease progression stage as well as the 
assignment of costs/QALYs or other relevant 
health/economic outcomes at a given cycle/me
3- Result calculaons: this verificaon stage checks the 
result calculaons that yield the undiscounted/ 
discounted total and incremental results (e.g. costs, 
QALYs, other relevant health or economic outcomes 
and ICER)
4- Uncertainty analysis: this verificaon stage checks 
the uncertainty analysis calculaons (e.g. one-way, 
mul-way, probabilisc sensivity, value of 
informaon and scenario analyses) 1
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Pre-requisite for conducng verificaon tests: 
Locang the calculaons in the model and the explanaon of the calculaons in 
the report. Assess the appropriateness of the methods. Check the completeness 
and consistency of the calculaons in the model
• (Report the sheets/ranges/coding lines where the corresponding 
calculaons are carried out in the electronic model, report any 
provided jusficaon for the methods/ assumpons used. Assess if 
these are appropriate with respect to the published methodological 
guidelines. Document the consistency checks that are conducted)
Verificaon tests aer the pre-requisite steps are complete:
Check if the implementaon of these calculaons is correct using black-box 
type, white-box type and replication-based tests, in a consecuve order, 
following the hierarchical order in Figure 3 under a me constraint.
• (Report all the necessary details of any test conducted, so that it can 
be reproduced by another reviewer, for each of the idenfied 
calculaons in the electronic model.)  
5- Overall tests (validaon or other supplementary tests): these tests include validaon efforts from other sources and tests that are applied to the whole 
model and efforts that do not specifically belong to one of the compartmentalized modules
• Compare the model outcomes with clinical inputs used in the model, findings from the literature, clinical expert knowledge and other model outcomes 
(Outline the conducted comparisons between the electronic model and the other sources and report if there is any inconsistency)
• Check the other aspects of model implementaon that does not fall under the scope of the other stages, such as the interface, programming and data 
storage efficiency, etc. (Report all the necessary details of any test conducted, so that it can be reproduced by another reviewer)
TECH-VER TECHnical VERification, QALYs quality-adjusted life-years, ICER incremental cost-effectiveness ratio
Fig. 3  Representation of the recommended hierarchical order of the type of the verification tests under a time constraint for the first four stages 
of TECH-VER
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Table 2  List of black-box tests
Test description (please also document how the test is conducted) Expected result of the test
Pre-analysis calculations
Does the technology (drug/device, etc.) acquisition cost increase 
with higher prices?
Yes
Does the drug acquisition cost increase for higher weight or body 
surface area?
Yes
Does the probability of an event, derived from an OR/RR/HR and 
baseline probability, increase with higher OR/RR/HR?
Yes
In a partitioned survival model, does the progression-free survival 
curve or the time on treatment curve cross the overall survival 
curve?
No
If survival parametric distributions are used in the extrapolations or 
time-to-event calculations, can the formulae used for the Weibull 
(generalized gamma) distribution generate the values obtained 
from the exponential (Weibull or Gamma) distribution(s) after 
replacing/transforming some of the parameters?
Yes
Is the HR calculated from Cox proportional hazards model applied 
on top of the parametric distribution extrapolation found from the 
survival regression?
No, it is better if the treatment effect that is applied to the extrapolation 
comes from the same survival regression in which the extrapolation 
parameters are estimated
For the treatment effect inputs, if the model uses outputs from 
WINBUGS, are the OR, HR, and RR values all within plausible 
ranges? (Should all be non-negative and the average of these 
WINBUGS outputs should give the mean treatment effect)
Yes
Event-state calculations
Calculate the sum of the number of patients at each health state Should add up to the cohort size
Check if all probabilities and number of patients in a state are 
greater than or equal to 0
Yes
Check if all probabilities are smaller than or equal to 1 Yes
Compare the number of dead (or any absorbing state) patients in a 
period with the number of dead (or any absorbing state) patients in 
the previous periods?
Should be larger
In case of lifetime horizon, check if all patients are dead at the end 
of the time horizon
Yes
Discrete event simulation specific: Sample one of the ‘time to event’ 
types used in the simulation from the specified distribution. Plot 
the samples and compare the mean and the variance from the 
sample
Sample mean and variance, and the simulation outputs, should reflect the 
distribution it is sampled from
Set all utilities to 1 The QALYs accumulated at a given time would be the same as the life-
years accumulated at that time
Set all utilities to 0 No utilities will be accumulated in the model
Decrease all state utilities simultaneously (but keep event-based util-
ity decrements constant)
Lower utilities will be accumulated each time
Set all costs to 0 No costs will be accumulated in the model at any time
Put mortality rates to 0 Patients never die
Put mortality rate at extremely high Patients die in the first few cycles
Set the effectiveness-, utility-, and safety-related model inputs for all 
treatment options equal
Same life-years and QALYs should be accumulated for all treatment at 
any time
In addition to the inputs above, set cost-related model inputs for all 
treatment options equal
Same costs, life-years, and QALYs should be accumulated for all treat-
ment at any time
Change around the effectiveness-, utility- and safety-related model 
inputs between two treatment options
Accumulated life-years and QALYs in the model at any time should also 
be reversed
Check if the number of alive patients estimated at any cycle is in 
line with general population life-table statistics
At any given age, the percentage alive should be lower or equal in com-
parison with the general population estimate
Check if the QALY estimate at any cycle is in line with general 
population utility estimates
At any given age, the utility assigned in the model should be lower or 
equal in comparison with the general population utility estimate
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Table 2  (continued)
Test description (please also document how the test is conducted) Expected result of the test
Set the inflation rate for the previous year higher The costs (which are based on a reference from previous years) assigned at 
each time will be higher
Calculate the sum of all ingoing and outgoing transition probabili-
ties of a state in a given cycle
Difference of ingoing and outgoing probabilities at a cycle in a state  times 
the cohort size will yield the change in the number of patients at that 
state in that cycle
Calculate the number of patients entering and leaving a tunnel state 
throughout the time horizon
Numbers entering = numbers leaving
Check if the time conversions for probabilities were conducted cor-
rectly.
Yes
Decision tree specific: Calculate the sum of the expected probabili-
ties of the terminal nodes
Should sum up to 1
Patient-level model specific: Check if common random numbers are 
maintained for sampling for the treatment arms
Yes
Patient-level model specific: Check if correlation in patient charac-
teristics is taken into account when determining starting popula-
tion
Yes
Increase the treatment acquisition cost Costs accumulated at a given time will increase during the period when 
the treatment is administered
Population model specific: Set the mortality and incidence rates to 0 Prevalence should be constant in time
Result calculations
Check the incremental life-years and QALYs gained results. Are 
they in line with the comparative clinical effectiveness evidence of 
the treatments involved?
If a treatment is more effective, it generally results in positive incremental 
LYs and QALYs in comparison with the less-effective treatments
Check the incremental cost results. Are they in line with the treat-
ment costs?
If a treatment is more expensive, and if it does not have much effect on 
other costs, it generally results in positive incremental costs
Total life years greater than the total QALYs Yes
Undiscounted results greater than the discounted results Yes
Divide undiscounted total QALYs by undiscounted life years This value should be within the outer ranges (maximum and minimum) of 
all the utility value inputs
Subgroup analysis results: How do the outcomes change if the char-
acteristics of the baseline change?
Better outcomes for better baseline health conditions, and worse outcomes 
for worse health conditions, are expected
Could you generate all the results in the report from the model 
(including the uncertainty analysis results)?
Yes
Do the total life-years, QALYs, and costs decrease if a shorter time 
horizon is selected?
Yes
Is the reporting and contextualization of the incremental results 
correct?
The use of terms such as ‘dominant’/‘dominated’/‘extendedly 
dominated’/‘cost effective’. etc.. should be in line with the results
In the incremental analysis table involving multiple treatments, ICERs 
should be calculated against the next non-dominated treatment
Are the reported ICERs in the fully incremental analysis non-
decreasing?
Yes
If disentangled results are presented, do they sum up to the total 
results (e.g. different cost types sum up to the total costs esti-
mate)?
Yes
Check if half-cycle correction is implemented correctly (total life-
years with half-cycle correction should be lower than without)
The half-cycle correction implementation should be error-free. Also check 
if it should be applied for all costs, for instance if a treatment is adminis-
tered at the start of a cycle, half-cycle correction might be unnecessary
Check the discounted value of costs/QALYs after 2 years Discounted value = undiscounted/(1 + r)2
Set discount rates to 0 The discounted and undiscounted results should be the same
Set mortality rate to 0 The undiscounted total life-years per patient should be equal to the length 
of the time horizon
Put the consequence of adverse event/discontinuation to 0 (0 costs 
and 0 mortality/utility decrements)
The results would be the same as the results when the AE rate is set to 0
Divide total undiscounted treatment acquisition costs by the average 
duration on treatment
This should be similar to treatment-related unit acquisition costs
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Table 2  (continued)
Test description (please also document how the test is conducted) Expected result of the test
Set discount rates to a higher value Total discounted results should decrease
Set discount rates of costs/effects to an extremely high value Total discounted results should be more or less the same as the discounted 
results accrued in the first cycles
Put adverse event/discontinuation rates to 0 and then to an extremely 
high level
Less costs and higher QALYS/LYs when adverse event rates are 0, higher 
costs and lower QALYS/LYs when AE rates are extreme
Double the difference in efficacy and safety between the new inter-
vention and comparator, and report the incremental results
Approximately twice the incremental effect results of the base case. If this 
is not the case, report and explain the underlying reason/mechanism
Do the same for a scenario in which the difference in efficacy and 
safety is halved
Approximately halve of the incremental effect results of the base case. If 
this is not the case, report and explain the underlying reason/mechanism
Uncertainty analysis calculations
Are all necessary parameters subject to uncertainty included in the 
OWSA?
Yes
Check if the OWSA includes any parameters associated with joint 
uncertainty (e.g. parts of a utility regression equation, survival 
curves with multiple parameters)
No
Are the upper and lower bounds used in the one-way sensitivity 
analysis using confidence intervals based on the statistical distri-
bution assumed for that parameter?
Yes
Are the resulting ICER, incremental costs/QALYs with upper and 
lower bound of a parameter plausible and in line with a priori 
expectations?
Yes
Check that all parameters used in the sensitivity analysis have appro-
priate associated distributions – upper and lower bounds should 
surround the deterministic value (i.e. upper bound ≥ mean ≥ lower 
bound)
Yes
 Standard error and not standard deviation used in sampling Yes
 Lognormal/gamma distribution for HRs and costs/resource use Yes
 Beta for utilities and proportions/probabilities Yes
 Dirichlet for multinomial Yes
 Multivariate normal for correlated inputs (e.g. survival curve or 
regression parameters)
Yes
 Normal for other variables as long as samples do not violate the 
requirement to remain positive when appropriate
Yes
Check PSA output mean costs, QALYs, and ICER compared with 
the deterministic results. Is there a large discrepancy?
No (in general)
If you take new PSA runs from the Microsoft Excel model do you 
get similar results?
Yes
Is(are) the CEAC line(s) in line with the CE scatter plots and the 
efficient frontier?
Yes
Does the PSA cloud demonstrate an unexpected behavior or have an 
unusual shape?
No
Is the sum of all CEAC lines equal to 1 for all WTP values? Yes
Do the explored scenario analyses provide a balanced view on the 
structural uncertainty (i.e. not always looking at more optimistic 
scenarios)?
Yes
Are the scenario analysis results plausible and in line with a priori 
expectations?
Yes
Check the correlation between two PSA results (i.e. costs/QALYs 
under the SoC and costs/QALYs under the comparator)
Should be very low (very high) if different (same) random streams are 
used for different arms
If a certain seed is used for random number generation (or previ-
ously generated random numbers are used), check if they are scat-
tered evenly between 0 and 1 when they are plotted
Yes
Compare the mean of the parameter samples generated by the model 
against the point estimate for that parameter; use graphical meth-
ods to examine distributions, functions
The sample means and the point estimates will overlap, the graphs will be 
similar to the corresponding distribution functions (e.g. normal, gamma, 
etc.)
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progression, time to death after progression is again re-
sampled, using the same distribution, as if the patient has 
just progressed. This led to an overestimation of the post-
progression survival, when the extrapolation distribution 
of choice was different from exponential. This error could 
have been detected by the black-box tests suggested for 
verification stage 2 (event/state calculations), for instance 
by checking if the simulated time to event reflects the dis-
tribution the time to event is sampled from.
• Errors in assignment of costs and utilities: In one of the 
student group models for the health economics graduate-
level course project, errors were detected in the assign-
ment of cost and utilities to the relevant events/states. 
For instance, in one of the group’s models, the expensive 
drug costs were assigned as long as the patients were 
alive even though the drug could be administered 10 
cycles at maximum. In another example, it was detected 
that the treatment-specific utility estimates for interven-
tions A and B were assigned in the opposite way it should 
have been. These errors were detected using white-box 
tests, after they were identified by replication-based tests, 
while comparing the utilities and costs accrued per cycle 
with those from parallel models (other black-box-type 
tests could have also identified these errors).
• Errors in the assignment of costs: In the NICE submis-
sion of ramucirumab for gastric cancer [20], hospitaliza-
tion rates derived from the primary trial were assigned at 
each cycle. These hospitalizations also included those due 
to adverse events; however, the adverse event costs were 
assigned separately at each cycle, which also included 
costs due to hospitalization. This led to a double counting 
of adverse events associated with hospitalization costs. 
This error was detected during white-box testing and 
assessing the appropriateness of the calculations for veri-
fication stage 2, conducted for the event/state calculations.
3.2.3  Verification Stage 3: Result Calculations
This verification stage focuses on the result calculations in 
the electronic model, which can be categorized as follows:
• summation of the accumulated costs, QALYs, and life-
years or other outcomes over time to obtain total costs, 
QALYs, and life-years or other total outcomes.
• the calculation and interpretation of the incremental 
results and ICER(s).
• applying half-cycle correction/discount rates.
• disaggregation of total costs and total QALYs.
• other calculations.
The errors that can be detected in this verification stage 
might have a direct impact on the incremental results and 
cost-effectiveness conclusions. The crucial calculations that 
need to be checked with white-box testing can be the way 
Table 2  (continued)
Test description (please also document how the test is conducted) Expected result of the test
Check if sensitivity analyses include any parameters associated with 
methodological/structural uncertainty (e.g. annual discount rates, 
time horizon)
No
Value of information analysis if applicable: Was this implemented 
correctly?
Yes
Which types of analysis? Were aggregated parameters used? Which 
parameters are grouped together? Does it match the write-up’s 
suggestions?
Yes
Is EVPI larger than all individual EVPPIs? Yes
Is EVPPI for a (group of) parameters larger than the EVSI of that 
(group) of parameter(s)?
Yes
Are the results from EVPPI in line with OWSA or other parameter 
importance analysis (e.g. ANCOVA)?
Yes
Did the electronic model pass the black-box tests of the previous 
verification stages in all PSA iterations and in all scenario analysis 
settings? (Additional macro can be embedded to the PSA code, 
which stops the PSA when an error such as negative transition 
probability is detected)
Yes
Check if all sampled input parameters in the PSA are correctly 
linked to the corresponding event/state calculations 
Yes
OWSA one-way sensitivity analysis, ICER incremental cost-effectiveness ratio, PSA probabilistic sensitivity analysis, WTP willingness to pay, 
CE cost effectiveness, CEAC cost-effectiveness acceptability curve, LY life-years, QALYs quality-adjusted life-years, OR odds ratio, RR relative 
risk, HR hazard ratio, SoC standard of care, EVPI expected value of perfect information, EVPPI expected value of partial perfect information, 
EVSI expected value of sample information, ANCOVA analysis of covariance
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total discounted and half-cycle corrected costs and QALYs 
are summed up and the way ICERs are derived, and how the 
costs and QALYs are disaggregated.
Some real-life examples
• Error in half-cycle correction: In one of the previous 
models the first author of this study had developed, an 
error was detected in the implementation of the half-cycle 
correction. Instead of summing over n-1 half-cycle-cor-
rected intervals from n cells, where each cell represented 
the QALYs accrued at the corresponding cycle, the author 
summed over n half-cycle-corrected intervals from n+1 
cells. Unfortunately, the value at the (n+1)th cell was not 
the QALYs that would be accrued at the (n+1)th cycle, 
but was the sum of the total QALYs accrued in the first n 
cycles. This error could have been detected by some of the 
black-box-type tests from TECH-VER, such as checking 
if half-cycle corrected total QALYs were lower than total 
QALYs that were not half-cycle corrected.
• Error in discount rate: In one of the student group mod-
els for the health economics graduate-level course pro-
ject, errors were detected in the discounting. Namely, in 
month t, an accrued cost of c was discounted as (
c
(1+0.035∕12)
)
t
 , whereas it should have been discounted as (
c
(1+0.035)
)
t∕12
 . This error could have been detected by 
checking if the discounted value from the model was 
c
(1+0.035)
 when t = 12.
• Error in ICER calculations: In one of the student group 
models for the health economics graduate-level course 
project, cost calculations were, in general, correct, but 
when presenting the disaggregated costs, the students 
assigned the administration cost of chemotherapy under 
both the ‘chemotherapy-related costs’ and the ‘resource 
use-related costs’, which led to double counting. This 
error could have been detected if the sum of the disag-
gregated costs was compared with the total costs.
• Error in ICER calculations: In the thesis of one of the Mas-
ters students, an error in the fully incremental analysis cal-
culations was detected. Instead of calculating the ICER with 
respect to the previous cost-effective technology, the student 
calculated the ICER with respect to the cheaper technology. 
This error could have been detected by the black-box-type 
tests in TECH-VER (e.g. checking if the reported ICERs in 
the fully incremental analysis were always non-decreasing).
3.2.4  Verification Stage 4: Uncertainty Analysis 
Calculations
In this part, the calculations related to uncertainty analysis 
in the model are tested. These analyses attempt to quan-
tify different aspects of parametric, structural, and decision 
uncertainty. The calculations in these modules can be cat-
egorized as below:
• one-way/multiway sensitivity analysis calculations.
• probabilistic sensitivity analysis (PSA) calculations.
• scenario analysis calculations.
• value of information (VOI) analysis calculations.
• other types of calculations.
Some real-life examples
• Error in PSA and one-way sensitivity (OWSA) calcula-
tions: In the NICE company submission for glecaprevir/
pibrentasvir for hepatitis C [21], 100% sustained viral 
response (primary effectiveness measure) was achieved 
for the genotype 5 subgroup, based on a small sample of 
patients. The company assumed the standard error for 
that parameter as zero since no events were observed for 
no response. This led to a substantial underestimation of 
the parametric uncertainty. The ERG detected this error 
in the ‘completeness and consistency’ checks for the pre-
requisite steps of verification stage 4, conducted for PSA 
calculations. After implementing a standard continuity 
correction for zero cells to obtain standard error esti-
mates, the impact on the PSA and OWSA results were 
substantial (i.e. the probability that glecaprevir/pibren-
tasvir becomes cost effective for that specific genotype 
reduces by 66%, and, in the OWSA, the viral response 
rate became by far the most influential parameter).
• Omitting the correlation between the regression coeffi-
cients: In one of the student group models for the health 
economics graduate-level course project, the students 
omitted the correlation between the regression coef-
ficients for the Weibull OS extrapolation. This led to 
overestimation of the parametric uncertainty to some 
extent. The error was detected based on assessing the 
PSA cloud from the students’ model, which seemed to 
be substantially more scattered than the PSA cloud of the 
other group’s model.
• Errors in sampled progression-free survival (PFS) and 
OS curves: In one of the student group models for the 
health economics graduate-level course project, the 
regression coefficients used for PFS and OS extrapola-
tion were sampled independently. In some of the PSA 
iterations, the students had a negative number of cohorts 
in the progressed disease state, which was calculated 
from (OS(t)-PFS(t)). The error was detected by the lec-
turers because there was a substantial unexplainable gap 
between the deterministic base-case cost outcomes and 
mean cost outcomes from the PSA iterations; however, 
the error could have also been detected if an automated 
check for negative numbers in the cohort trace was inte-
grated to the PSA for loop test.
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The errors that can be detected in this verification stage 
might lead to biased estimation of the uncertainty in the cost-
effectiveness outcomes from the model. For instance, if not 
all relevant parameters are sampled in the PSA, the paramet-
ric uncertainty will be underestimated and the model out-
comes will appear to be more certain than they actually are. 
Similarly, if the confidence interval of an input parameter was 
wrongly calculated for an OWSA, the relevant importance for 
that parameter would be misleading. If a wrong distribution 
is used while sampling a parameter in a PSA and VOI analy-
sis, the decision uncertainty results and subsequent future 
research recommendations may be unjustified.
Similar to the previous stages, after the prerequisite com-
pleteness and consistency checks have been completed, the 
model reviewer is advised to follow the hierarchical order 
outlined in Fig. 3, while conducting black-box, white-box 
and replication-based verification tests, in a hierarchical 
order.
3.2.5  Verification Stage 5: Overall Validation/Other 
Supplementary Tests
This verification stage involves checks that did not fall 
within the remit of the other verification stages, such as 
verification of the model interface or checking the model 
performance/programming inefficiencies.
These checks are important because a wrong interface 
switch button from an electronic model will lead to erratic 
results in the future. It should be ensured that all settings, 
switches, and other buttons used in the user interface of the 
electronic model operate correctly as per their intended use. 
Similarly, extremely slow models indicate inefficient pro-
gramming or unnecessary data storage, which might lead 
to numerical inconsistencies or even program/computer 
crashes. For this purpose, the programming of the model 
should be assessed, the necessity of all stored data in the 
model should be reconsidered, and extra-long formulas and 
nested loops should be flagged for double checking.
In addition, some of the validation checks that can be 
considered beyond the scope of verification (e.g. internal 
validation or cross-validation) can be conducted at this stage. 
These validation efforts can also be helpful in identifying 
model errors.
The reviewer can prepare a number of validation-based 
tests in this verification stage. For example, if the outcomes 
of a clinical study have been used in the pre-analysis cal-
culations, these can be compared with the model outcomes 
(e.g. comparing the median survival in the model versus 
median survival in the RCT used in generating the inputs 
of the model). Similarly, if the reviewer has another model 
in the same indication, and the two models have common 
comparators, the outcomes from the two models belonging 
to the common comparators can be contrasted.
Furthermore, if other cost-effectiveness results are avail-
able from the literature, the reviewer can try to check if the 
model under review can simulate the results from the litera-
ture when the baseline characteristics and the inputs used in 
the model are changed accordingly.
Some real-life examples
• Comparing the model outcomes with another model out-
come: In the NICE submission for ribociclib in breast 
cancer [22], the company submission model generated 
noticeably different outcomes in comparison to the out-
comes from the palbociclib NICE submission model, in 
the best supportive care treatment arms from both mod-
els. Even though this difference was later attributed to 
different model structure assumptions and not a model-
ling error, this difference in outcomes triggered the ERG 
to take an even more detailed look at the company’s 
model implementation, which led to the identification of 
additional errors.
• Model interface problems: In one of the country adapta-
tions of a model for an oncology product, the button on 
the main page of the model called “Back to the base-case 
assumptions” updated the input parameters that were dif-
ferent from the inputs used in the base-case.
If the model provides significantly different results than 
the results from the literature, this might indicate an error 
in the model implementation, although obviously it is also 
possible that the published model contains errors, or the dif-
ference in costs can be due to differences in concepts. There-
fore, it should be noted that these tests should be conducted 
in coordination with the efforts associated with the other 
validation tests (such as AdVISHE) [5] to avoid overlap of 
validation/verification efforts.
4  Discussion and Conclusion
In this current study, we introduced the TECH-VER check-
list, which is, to the best of the authors’ knowledge, the first 
attempt to create an open source, operational checklist to 
support the technical verification process of health economic 
decision analytical models. However, it is recognized that 
many institutions creating health economic models may 
already use their own in-house verification checklists.
The TECH-VER checklist consists of five verification 
stages, each of which focuses on the verification of different 
aspects of a decision analytical model. For each compart-
mentalized module calculation-related verification stage, 
we suggested a list of different types of verification tests 
(completeness/consistency as a prerequisite check, black-
box, white-box and replication-based tests), each should 
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be designed and conducted by the reviewer/validator in a 
necessity-based order, taking time constraints into account. 
A hierarchical order is suggested by the authors, which pri-
oritizes the black-box-type tests, and more time-consuming 
tests are reserved for a priori selected essential calculations 
or when black-box tests signal unexpected model behavior. 
A comprehensive list of black-box-type tests are also pre-
sented in this paper, which can be used by readers while 
they are designing their own black-box test suites specific 
for their models.
The TECH-VER checklist aims to provide a documenting 
framework for verification efforts, which would improve the 
transparency and efficiency of verification efforts and help 
identify modeling errors and their root causes in a more sys-
tematic manner. Furthermore, unexperienced, new health eco-
nomic modelers can use TECH-VER as a self-learning tool 
since they can integrate some of the verification tests while 
they are building their model. A simplified version of this 
checklist is being used in the peer review process of a Mas-
ters-level course on health economic modeling at our institute. 
As these students are new to modeling, having a tool to guide 
them in the process of peer reviewing models has proven to 
be very valuable. In addition, the TECH-VER checklist (with 
different levels of detail requirements) can be integrated into 
multi-team validation efforts in the model development pro-
cess, and can also be incorporated into HTA submissions for 
reimbursement purposes. Ultimately, our checklist might also 
be requested for manuscripts describing modeling studies sub-
mitted to scientific journals for publication.
The detailed documentation of the verification tests will 
improve the replicability of the verification efforts, meaning 
that in the next review rounds more time can be invested 
in thinking of additional tests/checks, such as extending 
the original list of black-box-type tests or extending the set 
of essential calculations to be scrutinized/replicated. The 
authors are aware that verification tests are model-specific 
and, without a doubt, other useful black-box tests are availa-
ble that are not mentioned in this study. Therefore, initiatives 
such as sharing the verification tests in open-source plat-
forms such as github, as suggested by Dasbach and Elbasha 
[6], are very important. For this reason, TECH-VER has also 
been published on an open-access online platform,1 together 
with some applications from the authors. On this platform, 
the validators can upload their own tests, put comments, and 
share their own experiences on verification/model errors and 
other practical examples.
We acknowledge that consultations with the health 
economic modeling experts outside of our institute (Eras-
mus University Rotterdam) were conducted during scien-
tific meetings and did not follow a formal Delphi method 
approach. Even though a Delphi approach would be more 
systematic, the level of detail involved in defining the checks 
and tests would make the realization of the Delphi approach 
extremely difficult. We also believe that different inputs from 
experts from other institutions, both from the Netherlands 
as well as from the other countries and stakeholders other 
than academia, were incorporated into the final version of 
the TECH-VER, and also believe that after publication of the 
TECH-VER, different stakeholders will be able to include 
their comments/feedback on the online platform where 
TECH-VER has been uploaded.
We would like to emphasize that the TECH-VER check-
list is aimed to serve as a documentation framework. The 
reviewer/validator is flexible on the type and amount of tests 
to be conducted, however it is recommended to document 
the verification efforts, which are conducted and which are 
omitted, together with the validators’ reasons for omission. 
We acknowledge that some of the verification tests are model-
dependent and cannot be applicable for all models. The black-
box list test we provided is comprehensive, but the reviewer/
validator is flexible to choose the tests in a different priority 
order, based on what they consider to be the most useful in 
their specific setting. For instance, a reviewer/validator, after 
feeling confident about the expected value of partial perfect 
information (EVPPI) calculations, can first conduct an EVPPI 
analysis to identify the most influential parameters on decision 
uncertainty, and focus on verification of the calculations on 
these parameters. Similarly, a model reviewer/validator might 
choose to conduct  replication-based testing for calculations, 
after the black-box tests resulted in unexpected model behav-
iors, and scrutinizing the calculations as part of white-box 
testing was not possible due to inaccessible codes in the eco-
nomic model. The TECH-VER framework accomodates such 
flexibilities, as long as the reviewer/validator documents the 
conducted as well as the omitted verification efforts in detail, 
along with the reasons for the omission.
Some of the practical examples presented in this paper 
originated from students’ models/projects from Erasmus 
University Rotterdam. The errors identified from the stu-
dents’ models can be reflective of the type of errors one 
might make as a junior modeler. Therefore, applying some 
of the tests provided in TECH-VER during the model devel-
opment phase can decrease the amount of errors in the final 
model. Other practical examples from different stakeholders 
(e.g. submitted NICE appraisal models from industry/con-
sultancy companies, or authors’ own models) can be repre-
sentative of the types of errors one might make as a more 
senior modeler, or with different motivation of biases. We 
believe that in the online platform where the TECH-VER has 
been published, different stakeholders will be able to share 
more practical examples and verification strategies.
The authors consider that it would be most efficient if 
TECH-VER is used in conjunction with other validation 
1 https ://githu b.com/nasuh cagda s/TECHV ER and http://www.imta.
nl/techv er.
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efforts (e.g. conceptual or face validity) as these efforts are 
highly interdependent and verification of a conceptually 
wrong model (e.g. a model that estimates total life expec-
tancy of a cohort by rolling a die) would be a waste of time. 
On the other hand, model validity is conditional on its veri-
fication because a wrongly implemented model would auto-
matically fail to accurately represent the real world, even 
though its conceptualization was right.
Completion of the checklist steps and resolving the 
detected errors should not be interpreted as a guarantee that 
the model is free of errors. Error detection is dependent on 
multiple aspects, including the reviewer’s/validator’s expe-
rience, as well as the reviewer’s attention level at the time 
of verification. Therefore, the TECH-VER checklist does 
not intend to score the verification status of a model as that 
might give a false sense of security and cause overconfi-
dence in the model, or might lead to using such a score out 
of context, such as arguing that a model with a higher score 
is better than the other model.
Similar to the validation status of a model, final judgment 
of the verification status of the model will always be a sub-
jective judgment by the end-user of the model. However, the 
TECH-VER checklist aims to present an objective, transpar-
ent way of documenting and sharing information between 
different model users and model reviewers. In addition, it 
aims to assist the end-user’s final judgment on the mod-
el’s verification status by using a transparent documenting 
framework. This framework includes replicable tests, encap-
sulating all relevant parts of a typical decision analytical 
model. Therefore, verification checklists such as the TECH-
VER checklist should be an integral part of the lifecycle of 
health economic decision analytical models.
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Table 3  Literature review strategy using the Embase.com interface
#6 #5 AND ([embase]/lim OR ([medline]/lim NOT ([embase classic]/lim AND [medline]/lim))) AND (‘Article’/it OR ‘Article in 
Press’/it)
3500
#5 #3 AND #4 8152
#4 checklist:ab,ti OR valida*:ab,ti OR validi*:ab,ti OR verify*:ab,ti OR verifi*:ab,ti OR error:ab,ti OR guideline*:ab,ti OR 
credib*:ab,ti OR questionnaire*:ab,ti
2,272,728
#3 #1 AND #2 42,232
#2 ‘economic model’ OR ‘simulation’/de OR (‘model’/de AND (‘economics’/exp OR ‘economic aspect’/exp)) OR ‘decision tree’/
de OR (((model OR modeling OR modelling OR simulation* OR microsimulation*) NEAR/6 (econom* OR pharmaco-
econom* OR cost OR costs)):ab,ti) OR ((decision NEAR/3 (analy* OR tree OR trees)):ab,ti) OR ‘discrete event*’:ab,ti OR 
‘state transition’:ab,ti OR markov:ab,ti OR (((individual* OR ‘patient level*’) NEAR/3 (sampl* OR simulation*)):ab,ti) OR 
((dynamic NEAR/3 transmission*):ab,ti) OR probabilistic*:ab,ti OR ‘partition* survival*’:ab,ti OR ‘he model*’:ab,ti OR 
((economic NEAR/1 submission*):ab,ti)
295,055
#1 ‘biomedical technology assessment’/exp OR ‘economic evaluation’/exp OR ‘quality adjusted life year’/exp OR ‘program cost 
effectiveness’/de OR ((technology NEAR/3 assessment*):ab,ti) OR ((economic* NEAR/3 (evaluat* OR value)):ab,ti) OR 
(((cost OR costs) NEAR/3 (benefit* OR effectiv* OR efficien* OR efficac* OR minim* OR utilit* OR consequen*)):ab,ti) 
OR ((qualit* NEAR/3 adjust* NEAR/3 (‘life year*’ OR lifeyear*)):ab,ti) OR qaly*:ab,ti OR ‘health econ*’:ab,ti OR 
pharmacoeconom*:ab,ti
431,838
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